Results 161 to 170 of about 364,712 (294)

Expert Perspectives: Defining and Managing Progressive Pulmonary Fibrosis in Systemic Sclerosis

Arthritis &Rheumatology, EarlyView.
Systemic sclerosis–associated interstitial lung disease (SSc‐ILD) is one of the leading causes of morbidity and mortality in SSc, affecting up to three‐quarters of patients. The disease course is highly heterogeneous, ranging from indolent, nonprogressive forms to rapidly progressive pulmonary fibrosis (PPF).
Devis Benfaremo, Dinesh Khanna, Corrado Campochiaro, Vincent Cottin, Fabrizio Luppi, Marco Matucci‐Cerinic, Gianluca Moroncini, Yannick Allanore   +7 more
wiley   +1 more source

Domain Specific Placebo Response in the Modified Friedreich's Ataxia Rating Scale. [PDF]

Ann Clin Transl Neurol
Rummey C, Farmer JM, Lynch DR.
europepmc   +1 more source

The Effectiveness of Acceptance and Commitment Therapy Group Intervention (Navigator ACT) for Parents of Children With Neurodevelopmental Disabilities: A Randomized Controlled Trial

Autism Research, EarlyView.
ABSTRACT High levels of parental stress and psychological inflexibility are common among caregivers raising children with neurodevelopmental disabilities. Navigator ACT is a group‐based treatment developed to increase psychological flexibility and reduce the impact of stress among parents of children with various disabilities (e.g., autism spectrum ...
T. Holmberg Bergman, P. Lappalainen, A. Ghaderi, T. Hirvikoski   +3 more
wiley   +1 more source

The Two Sides of Placebo Analgesia: Differential Functional Connectivity Reveals Mechanisms of Placebo Analgesic Response

Nicholas J Bush,1,2 Adriana K Cushnie,2 Jeff Boissoneault,1,2 Sharmagh Aghabeigi,1 Casey Alexander,1 Roland Staud,3 Michael E Robinson1 1Department of Clinical and Health Psychology, University of Florida, Gainesville, FL, USA; 2Department of ...
Robinson ME, Boissoneault J, Bush NJ, Alexander C, Staud R, Aghabeigi S, Cushnie AK   +6 more
core  

A Model-Based Meta-Analysis Framework Quantifying Drivers of Placebo Response in Atopic Dermatitis Trials. [PDF]

CPT Pharmacometrics Syst Pharmacol
Serrano JC, Maringwa J, Straetemans R, Willems W, Liva SG, Verhoeven J, Ford JL, Huang KG, Hubbard JJ, French JL, Devineni D, Vermeulen A, Valiathan C.   +12 more
europepmc   +1 more source

Cortical morphology predicts placebo response in multiple sclerosis. [PDF]

Sci Rep, 2022
Cherkasova MV, Fu JF, Jarrett M, Johnson P, Abel S, Tam R, Rauscher A, Sossi V, Kolind S, Li DKB, Sadovnick AD, Machan L, Girard JM, Emond F, Vosoughi R, Traboulsee A, Stoessl AJ.   +16 more
europepmc   +1 more source

Beyond the Outburst: Charting a New Frontier for Understanding and Treating Irritability in Autistic Adults

Autism Research, EarlyView.
ABSTRACT Irritability is a prevalent and impairing feature associated with autism, yet remains poorly understood, particularly in adults. Drawing heavily on insights translated from pediatric and transdiagnostic literatures, we propose that irritability in autistic individuals often reflects a psychophysiological stress or threat response, rooted in a ...
Hsiang‐Yuan Lin, Arthur N. Westover, Amy S. F. Lutz, Manish K. Jha   +3 more
wiley   +1 more source

Analyzing the Placebo Response and Identifying Influential Factors in Oral Medication Trials for Acute-Phase Schizophrenia. [PDF]

Schizophr Bull
Ren J, Zhang L, Xu L, Lv Y, Huang J, Feng Y, Guo H, Wang Y, Yang J, Zheng Q, Li L.   +10 more
europepmc   +1 more source

The Impact of Baseline Anxiety on Drug Placebo Separation and Drug/Placebo Response in an Acute Schizophrenia Clinical Trial-A Post-hoc Analysis. [PDF]

Schizophr Bull Open, 2023
Kott A, Brannan S, Wang X, Daniel D.
europepmc   +1 more source

Early‐stage health technology assessment of a curative gene therapy for multiple sclerosis

British Journal of Clinical Pharmacology, EarlyView.
Aims Multiple sclerosis (MS) is associated with significant early morbidity, reduced life expectancy and substantial healthcare and societal costs. The primary objective of this study is to assess the early cost‐effectiveness potential of a novel gene therapy, IMMUTOL, for MS compared with current high‐efficacy treatment sequences.
Attila Imre, Balázs Nagy, Rok Hren
wiley   +1 more source